Leadership

Craig Anderson
Chief Executive Officer

Craig Anderson is the founder and Chief Executive Officer of Apogee. A seasoned executive, entrepreneur, and investor with 40 years of business experience, Mr. Anderson began his career on Wall Street in the mid‑1980s, holding M&A and corporate finance roles at Merrill Lynch, Credit Suisse, and other investment banks in New York. He later founded and led a healthcare services company starting with three employees and grew it to approximately 2,000, culminating in a successful exit for himself and other investors. At Apogee, he leverages deep expertise in finance, operations, and corporate strategy to drive long‑term vision, operational execution, and strategic growth.

Blair Hogg JD, LLM and MBA
Chief Operating Officer and General Counsel

Blair Hogg serves as Chief Operating Officer and General Counsel of Apogee, bringing more than 20 years of leadership at the nexus of law, finance, and operations. With JD, LLM, and MBA degrees, Mr. Hogg bridges legal expertise with business and financial acumen. He has led complex, high‑value transactions, navigated regulatory frameworks, and built scalable organizations to support sustained growth. At Apogee, he oversees operational, financial, and legal functions to ensure disciplined execution as the company scales.

Katherine Radek, PhD
Senior Director of Biology

Dr. Katherine Radek is Senior Director of Biology at Apogee Pharmaceuticals, where she leads translational discovery at the intersection of immunology, women’s health, and precision medicine. With more than 16 years of experience spanning NIH‑funded academic research and pharmaceutical R&D, Dr. Radek brings deep expertise in epithelial biology, tissue repair, host defense, and immune‑mediated disease. Previously at GlaxoSmithKline (GSK), she directed cross‑functional teams in target identification, validation, and preclinical development across rheumatology and neurodegeneration, advancing novel assets from early discovery through key milestones. Earlier, as a tenured Associate Professor, she led research programs in immunodermatology and urogynecology, advancing understanding of pelvic floor dysfunction and pain syndromes. At Apogee, Dr. Radek integrates mechanistic biology with AI‑ and omics‑enabled discovery to build a precision pipeline of therapeutics and diagnostics for high‑unmet‑need conditions in women’s health.

Craig Volker, PhD
Director of Translational Medicine

Dr. Craig Volker is Director of Translational Medicine at Apogee. He has 25 years of drug discovery and development experience at GlaxoSmithKline (GSK) and has led high‑performing teams across informatics, chemistry, biology, and interdisciplinary research. An award‑winning scientist, Dr. Volker has played key roles in identifying and validating therapeutic targets and in advancing programs from discovery into development. He has also contributed to strategic decision‑making as a member of cross‑functional teams that evaluate external innovation and partnership opportunities. At Apogee, he ensures that foundational laboratory insights translate into viable clinical candidates and that scientific rigor is maintained from discovery through development.

Greg Ferguson, PhD
Senior Director of Pharmacology

Dr. Greg Ferguson is Senior Director, Pharmacology at Apogee Pharmaceuticals. An experienced drug hunter with more than 20 years in biopharma (Celgene, Ferring), including nearly a decade focused on women’s reproductive health, he developed strong disease‑area expertise at Ferring, led a global cross‑functional discovery team, and collaborated with KOLs on high‑impact publications. Dr. Ferguson brings broad preclinical experience across HTS through IND stage and has supported translational and early clinical programs. He has validated drug targets, developed disease‑relevant assays and models, and designed screening infrastructures across target classes and modalities.